Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer

Journal of Laboratory and Clinical Medicine

Volumn 147, Issue 4, 2006, Pages 174-181

  Kuvibidila, Solo ^a   Rayford, Walter ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The Research Institute for Children at Children's Hospital New Orleans   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; OROSOMUCOID; PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RACE DIFFERENCE; RISK ASSESSMENT;

ACUTE-PHASE PROTEINS; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645886619     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2005.11.012     Document Type: Article

References (51)

1. Travis J., and Salvesen G.S. Human plasma proteinase inhibitors. Annu Rev Biochem 52 (1983) 655-709
2. Tarvis J., Matheson N., and Johnson D. The interaction of α1-proteinase inhibitor with serine proteinase. In: Lundblad R.L., Fenton J.W., and Mann K.G. (Eds). Chemistry and biology of thrombin (1977), Ann Arbor Publication, Ann Arbor, Mich 431-440
3. Chawla R.K., Laweson D.H., Sarma R., Nixon D.W., and Travis J. Serum alpha-1 proteinase inhibitor in advanced cancer. mass variants and functionally inert forms. Cancer Res 47 (1987) 1179-1184
4. Gadek J.E., Fells G.A., Zimmerman R.L., Rennard S.I., and Crystal R.G. Antielastases of human alveolar structures. implications for the proteinase-antiproteinase theory of emphysema. J Clin Invest 68 (1981) 889-898
5. Wewers M.D., Casolaro M.A., and Crystal R.G. Comparison of α1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the α1-antitrypsin phenotype null-null before and during α1-antitrypsin and augmentation therapy. Am Rev Resp Dis 135 (1987) 539-543
6. Wolten J.M., Rodwell R.L., Bowler S.D., and McCormack J.G. Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis. Clin Diagn Lab Immunol 6 (1999) 260-265
7. Marta R.F., Montero V.S., Hack C.E., Sturk A., Maiztegui J.I., and Molinas F.C. Proinflammatory cytokines and elastase-α-1-antitrypsin in Argentine hemorrhagic fever. Am J Trop Med Hygiene 60 (1999) 85-89
8. McMillan D.C., Talwar D., Sattar N., Underwood M., O'Reilly D.S., and McArdle C. The relationship between reduced vitamin antioxidant concentrations and the systemic inflammatory response in patients with common solid tumors. Clin Nutr 21 (2002) 161-164
9. Daddi G., Mancini P.A., Parola D., and Contini A. α1-antitrypsin increase in lung cancer. Bollettino del Instituto Sieroterapico Milanese 55 (1976) 510-512
10. Tountas Y., Sparos L., and Theodoropoulas. Trichopoulos D. Alpha-1-antitrypsin and cancer of the pancreas. ??. Digestion 31 (1985) 37-40
11. Kaneti J., Winikoff Y., Zimlichman S., and Shainkin-Kestenbaum R. Importance of serum amyloid A level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res 12 (1984) 239-241
12. Buamah P.K., and Skillen A.W. Concentrations of protease and anti-proteinase in serum of patients with pancreatic cancer. Clin Chem 36 (1985) 876-877
13. Boskovic G., and Twing S.S. Local control of α1-proteinase inhibitor levels. regulation of α1-proteinase inhibitor in human cornea by growth factors and cytokines. Bioch Bioph Acta 1403 (1998) 37-46
14. Molle W.N., Libert C.L., Fiers W., and Brouckaert X. α1-acid glycoprotein and α1-antitrypsin inhibit TNF-induced but not anti-fas-induced apoptosis of hepatocytes in mice. J Immunol 159 (1997) 3555-3564
15. Costello L.C., Franklin R.B., and Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 38 (1999) 237-245
16. Nielsen M.L., Asnaes S., and Hattel T. Inflammatory changes in the non-infected prostate gland. A clinical, microbiological and histological investigation. J Urol 110 (1973) 423-426
17. Zhang W.E., Sesterhenn I.A., Connelly R.R., Mostofi F.K., and Moul J.W. Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol 163 (2000) 131-136
18. Hochreiter W., Duncan J.L., and Schaeffer A.J. Evaluation of the bacterial flora of the prostate using a 16s rRNA gene based polymerase chain reaction. J Urol 163 (2000) 127-130
19. Lucia M.S., and Torkko K.C. Inflammation as a target for prostate cancer chemoprevention. pathological and laboratory rationale. J Urol 171 (2004) S30-S35
20. DeMarzo A.M., Marchi V.L., Epstein J.I., and Nelson W.G. Proliferative inflammatory atrophy of the prostate. Implication for prostate cancer. Prostate 58 (2004) 121-129
21. Ward A.M., Cooper E.H., and Houghton A.L. Acute phase reactant proteins in prostate cancer. Brit J Urol 49 (1977) 411-418
22. Zietek Z., Iwan-Zietek I., Kotschy M., and Tyloch F. Activity of α1-antitrypsin in blood of patients with prostatic tumor. Polski Tygonik Lekarski 51 (1996) 89-90
23. Zietek Z., Iwan-Zietek I., Kotschy M., and Tyloch F. Activity of α1-antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate. Polski Tygodnik Lekarski 51 (1996) 77-78
24. Stephan C., Jung K., Lein M., et al. Molecular forms of protein specific antigen and human kallikrein-2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 9 (2000) 1133-1147
25. Stenman U.H., Leinnone J., Althan H., et al. A complex between protein specific antigen and α1-chymotrypsin is the major form of protein specific antigen in serum of patients with prostate cancer. assay of complex improves clinical sensitivity of cancer. Cancer Res 51 (1991) 222-226
26. Taneja S.S., Hsu E.I., and Cheli C.D. Complexed prostate specific antigen as a staging tool. results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology 60 suppl 4A (2002) 10-17
27. Zhang W.M., Finne P., Leinonen J., Vesalainen S., Nordling S., and Stenman U.H. Measurement of the complex between prostate-specific antigen and α1-proteiase inhibitor in serum. Clin Chem 45 (1999) 814-821
28. Morgan T.O., Jacobson S.J., McCarthy W.F., et al. Age specific reference range for prostate specific antigen levels in black men. New Engl J Med 335 (1996) 304-310
29. Fowller J.E., Bigler S.A., Bowwman G., and Kilambi N.K. Race and cause specific survival with prostate cancer. influence of clinical stage, Gleason score, age and treatment. J Urol 163 (2000) 137-142
30. Tewari A., Horninger W., Badani K.K., Hasan M., Coon S., Crawford E.D., et al. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 96 (2005) 29-33
31. Kyle C., Ewing T., Wu X.C., Mercante D., Lifsey D., Meunier C., et al. Statewide analysis of serum prostate specific antigen levels in Louisiana men without prostate cancer. J LA State Med Soc 156 (2004) 319-323
32. Osterling J.E. Prostate specific antigen. a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145 (1991) 907-923
33. Mancini G., Carbinaria A.O., and Heremans J.F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2 (1965) 2345-2354
34. Munro H.M., Visitainer M.A., and Page E.B. Statistical methods for health care research (1993), J.B. Lippincott, Philadelphia, Penn
35. Platz E.A., DeMarzo M.A., Erlinger T.P., Rifai N., Visvanathan K., Hoffman S.C., et al. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate 59 (2004) 393-400
36. Latif Z., McMillan D.C., Wallace A.M., Sattar N., Mir K., Jones G., et al. The relationship of circulating insulin-like growth factor-1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease state in prostate cancer. BJU Int 89 (2002) 396-399
37. Perlmutter D.H., May L.T., and Sehgal P.B. Interferon-beta-2/IL-6 modulates synthesis of α1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells. J Clin Invest 84 (1989) 138-144
38. Aronson W.J., and Freeland S.J. Editorial. can we lower the mortality rate of black men with prostate cancer?. J Urol 163 (2000) 150-151
39. Freeland S.J., Sutter M.E., Naitoh J., Dorey F., Csathy G., and Aronson W. Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology 55 (2000) 387-390
40. Fowler J.E., Bigler S.A., Bowman G., and Kilambi N.K. Race and cause specific survival with prostate cancer. influence of clinical stage, Gleason score, age, and treatment. J Urol 163 (2000) 137-142
41. Kataoka H., Seguchi K., Inoue T., and Koono M. Properties of α1-antitrypsin secreted by human adenocarcinoma cell lines. FEBS Lett 328 (1993) 291-295
42. Perlmutter D.H., Cole F.S., Kilbridge P., Rossing T.H., and Colten H.R. Expression of α1-proteinase inhibitor gene in human monocytes and macrophages. Proc Natl Acad Sci USA 82 (1985) 795-799
43. Isaacson P.D., Jones D.B., Milward-Sadler G.H., Judd M.A., and Payne S. α1-antitrypsin in human macrophages. J Clin Pathol 34 (1981) 982-990
44. Pannek J., Rittenhouse H.G., Chan D.W., Epstein J.I., Walsh P.C., and Partin A.W. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 159 (1998) 1238-1242
45. Abdalla I., Ray P., Ray V., Vaida F., and Vijayakumar S. Racial differences in prostate specific antigen levels and prostate specific antigen densities in patients with prostate cancer. Am J Clin Oncol 22 (1999) 537-541
46. Van Sande M., and Van Camp K. α1-antitrypsin, α2-macroglobulin and complement C4 in human benign prostatic hyperplasia. Urol Res 11 (1983) 275-277
47. Desrochers P.E., Jeffrey J.J., and Weiss S.J. Interstitial collagenase (matrix metalloproteinase-1) expresses serminase activity. J Clin Invest 88 (1991) 2258-2265
48. Kataoka H., Uchino H., Iwamura T., Seiki M., Nabeshima K., and Koono M. Enhanced tumor growth and invasiveness in vivo by carboxyl-terminal fragment of α1-proteinase inhibitor generated by matrix metalloproteinases. a possible modulator role in natural killer cytotoxicity. Am J Pathol 154 (1999) 457-468
49. Lisowska-Myjak B., and Pachecka J. Antigenic and functional levels of alpa-1-antitrypsin in serum during normal and diabetic pregnancy. Eur J Obs, Gynecol Reprod Biol 106 (2003) 31-35
50. Zelvyte I., Ohlsson B., Axelson J., and Janciauskiene S. Diverse responses between human pancreatic cancer cell lines to native alpha-1-antitrypsin and its C-terminal fragment. Anticancer Res 23 (2003) 2267-2273
51. Zelvyte I., Lindgren S., and Janciauskiene S. Multiple effects of α1-antitrypsin on breast carcinoma MDA-MB 468 cell growth and invasiveness. Eur J Cancer Prevention 12 (2003) 117-124